These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 10982266

  • 21. [Hemophilia, a changed picture].
    Breederveld C, ten Cate JW, Sixma JJ, Veltkamp JJ.
    Ned Tijdschr Geneeskd; 1976 Jan 10; 120(2):69-70. PubMed ID: 1250448
    [No Abstract] [Full Text] [Related]

  • 22. Suggestions for the management of factor VIII inhibitors.
    Rubinger M, Rivard GE, Teitel J, Walker H, Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada.
    Haemophilia; 2000 Jul 10; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract] [Full Text] [Related]

  • 23. Animal models of inhibitors.
    Reipert B, Arruda V, Lillicrap D.
    Haemophilia; 2010 Jul 10; 16 Suppl 5():47-53. PubMed ID: 20590856
    [Abstract] [Full Text] [Related]

  • 24. Inhibitors in young boys with haemophilia.
    Lusher JM.
    Baillieres Best Pract Res Clin Haematol; 2000 Sep 10; 13(3):457-68. PubMed ID: 11030045
    [Abstract] [Full Text] [Related]

  • 25. Recombinant clotting factors in the treatment of hemophilia.
    Lee C.
    Thromb Haemost; 1999 Aug 10; 82(2):516-24. PubMed ID: 10605745
    [No Abstract] [Full Text] [Related]

  • 26. How I manage patients with inherited haemophilia A and B and factor inhibitors.
    Ljung RCR.
    Br J Haematol; 2018 Feb 10; 180(4):501-510. PubMed ID: 29270992
    [Abstract] [Full Text] [Related]

  • 27. Advances in the treatment of hemophilia.
    Kessler CM.
    Clin Adv Hematol Oncol; 2008 Mar 10; 6(3):184-7. PubMed ID: 18391917
    [No Abstract] [Full Text] [Related]

  • 28. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH, Schwaab R, Effenberger W, Hess L, Hanfland P, Oldenburg J.
    Haematologica; 2000 Oct 10; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract] [Full Text] [Related]

  • 29. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR, Brown S, Collins PW, Keeling DM, Liesner R.
    Br J Haematol; 2006 Jun 10; 133(6):591-605. PubMed ID: 16704433
    [Abstract] [Full Text] [Related]

  • 30. Key issues in inhibitor management in patients with haemophilia.
    Gomez K, Klamroth R, Mahlangu J, Mancuso ME, Mingot ME, Ozelo MC.
    Blood Transfus; 2014 Jan 10; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
    [No Abstract] [Full Text] [Related]

  • 31. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC, Greenwood R, Escobar M, Frelinger JA.
    Haematologica; 2000 Oct 10; 85(10 Suppl):113-6. PubMed ID: 11187862
    [Abstract] [Full Text] [Related]

  • 32. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM, Berntorp E.
    Prog Clin Biol Res; 1990 Oct 10; 324():69-78. PubMed ID: 2106694
    [No Abstract] [Full Text] [Related]

  • 33. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR.
    Vox Sang; 1999 Oct 10; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract] [Full Text] [Related]

  • 34. Inhibitors in congenital haemophilia.
    Brettler DB.
    Baillieres Clin Haematol; 1996 Jun 10; 9(2):319-29. PubMed ID: 8800508
    [Abstract] [Full Text] [Related]

  • 35. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul 10; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 36. Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.
    Iioka F, Shimomura D, Nakamura F, Ohno H, Yada K, Nogami K, Shima M.
    Haemophilia; 2014 Nov 10; 20(6):e402-4. PubMed ID: 25354772
    [No Abstract] [Full Text] [Related]

  • 37. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
    Chuansumrit A, Sri-Udomporn N, Srimuninnimit V, Juntarukha R.
    Haemophilia; 2001 Sep 10; 7(5):532-4. PubMed ID: 11554948
    [No Abstract] [Full Text] [Related]

  • 38. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.
    DiMichele DM, Kroner BL, North American Immune Tolerance Study Group.
    Thromb Haemost; 2002 Jan 10; 87(1):52-7. PubMed ID: 11848456
    [Abstract] [Full Text] [Related]

  • 39. Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
    Di Minno MN, Marchesini E, Valdrè L.
    Blood; 2015 Jun 11; 125(24):3819-21. PubMed ID: 26069336
    [No Abstract] [Full Text] [Related]

  • 40. Factor VIII brand and immunogenicity.
    Ragni MV.
    Blood; 2014 Nov 27; 124(23):3337-8. PubMed ID: 25431473
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.